Clinical trial · no report yet · Phase 3
VIALE-T
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
- NCT04161885 ↗
- Terminated
- AbbVie
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 6 | |
| Podcasts | 2 | |
| Bluesky threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia (AML) (VIALE-T)
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Acute Myeloid Leukemia (AML); Cancer
- Interventions
- Venetoclax; Azacitidine; Best Supportive Care (BSC)
- Arms
- Part 1: Venetoclax + Azacitidine (AZA) + Best Supportive Care · Experimental
- Part 2: Arm B - Best Supportive Care (BSC) · Experimental
- Part 2: Arm A - Venetoclax + Azacitidine (AZA) + BSC · Experimental
- Enrollment
- 465
- Primary outcomes
- Number of Participants With Dose-Limiting Toxicities (DLTs) Following Administration of Venetoclax and Azacitidine (Part 1)
- Overall Survival (OS) (Part 2)
- Sponsor
- AbbVie
- Start
- Feb 26, 2020
- Primary completion
- Sep 23, 2025
- Results posted
- Yes
- Registry record
- NCT04161885 · updated Jun 4, 2026